HCA VS BSX Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

HCA
10/100

HCA returned 4.32% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

BSX
100/100

BSX returned 26.68% in the last 12 months. Based on SPY's performance of -12.97%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

HCA
75/100

22 analysts offer 12-month price targets for HCA. Together, they have an average target of 265.95, the most optimistic target put HCA at 315 within 12-months and the most pessimistic has HCA at 200.

BSX
79/100

24 analysts offer 12-month price targets for BSX. Together, they have an average target of 57.93, the most optimistic target put BSX at 132 within 12-months and the most pessimistic has BSX at 43.

Technicals

HCA
50/100

HCA receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

BSX
89/100

BSX receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

HCA
10/100

HCA has missed earnings 6 times in the last 20 quarters.

BSX
26/100

BSX has missed earnings 4 times in the last 20 quarters.

Profit

HCA
78/100

Out of the last 20 quarters, HCA has had 20 profitable quarters and has increased their profits year over year on 10 of them.

BSX
72/100

Out of the last 20 quarters, BSX has had 18 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

HCA
49/100

HCA has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

BSX
48/100

BSX has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Dividend

HCA
23/100

HCA's most recent dividend was $0.35 per share, based on a share price of $237.58. It was a payout ratio of 11.37% compared to their total earnings.

BSX
10/100

BSX's most recent dividend was $0.01 per share, based on a share price of $53.85. It was a payout ratio of -8.24% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

HCA Healthcare, Inc. Summary

New York Stock Exchange / HCA
Healthcare
Medical - Care Facilities
HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, the company operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. As of December 31, 2021, it operated 182 hospitals, including 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals; 125 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Boston Scientific Corp. Summary

New York Stock Exchange / BSX
Healthcare
Medical - Devices
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.